 |
|
|
| |
Futility Rules in Telaprevir Combination Treatment
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Ira M. Jacobson1, Doug J. Bartels2, Linda Gritz2, Tara L. Kieffer2, Sandra De Meyer3, Frank Tomaka4, Leif Bengtsson2, Don Luo4, Bambang S. Adiwijaya2, Robert S. Kauffman2, Gaston Picchio4, Nathalie Adda2
1Weill Cornell Medical College, New York, NY, United States; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 3Janssen Infectious Diseases BVBA, Beerse, Belgium; 4Janssen Research and Development, LLC, Titusville, New Jersey, United States
|
| |
|
|
|
|
|
